28 April 2020  
EMA/178688/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Taltz 
ixekizumab 
On 28 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Taltz. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted a new indication as follows: 
Axial spondyloarthritis 
Ankylosing spondylitis (radiographic axial spondyloarthritis) 
Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have 
responded inadequately to conventional therapy. 
Non-radiographic axial spondyloarthritis 
Taltz is indicated for the treatment of adult patients with active non-radiographic axial 
spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein 
(CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to 
nonsteroidal anti-inflammatory drugs (NSAIDs). 
For information, the full indications for Taltz will be as follows: 
Plaque psoriasis 
Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are 
candidates for systemic therapy. 
Psoriatic arthritis 
Taltz, alone or in combination with methotrexate, is indicated for the treatment of active 
psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to 
one or more disease-modifying anti-rheumatic drug (DMARD) therapies (see section 5.1). 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
Axial spondyloarthritis 
Ankylosing spondylitis (radiographic axial spondyloarthritis) 
Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have 
responded inadequately to conventional therapy. 
Non-radiographic axial spondyloarthritis 
Taltz is indicated for the treatment of adult patients with active non-radiographic axial 
spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein 
(CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to 
nonsteroidal anti-inflammatory drugs (NSAIDs). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Taltz  
EMA/178688/2020 
Page 2/2 
 
  
  
 
